Shares of Avid Bioservices CDMO rose 6.81% after the company reported Q1 results.
Quarterly Results
Earnings per share rose 175.00% over the past year to $0.06, which beat the estimate of ($0.07).
Revenue of $25,392,000 higher by 66.46% year over year, which beat the estimate of $16,500,000.
Outlook
The company is confirming revenue guidance for the full fiscal year 2021 of $76 million to $81 million.
How To Listen To The Conference Call
Date: Sep 01, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/64ateurd
Price Action
52-week high: $8.82
52-week low: $3.02
Price action over last quarter: Up 19.72%
Company Description
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
